| Literature DB >> 27803764 |
Jaqueline Ferreira Campos1, David Tsuyoshi Hiramatsu de Castro1, Marcio José Damião1, Heron F Vieira Torquato2, Edgar J Paredes-Gamero3, Carlos Alexandre Carollo4, Leticia M Estevinho5, Kely de Picoli Souza1, Edson Lucas Dos Santos1.
Abstract
Natural products can be a source of biomolecules with antioxidant activity which are able to prevent oxidative stress-induced diseases and show antitumor activity, making them important sources of new anticancer drug prototypes. In this context, this study aimed to analyze the chemical composition of an ethanol extract of Senna velutina leaves and to assess its antioxidant and cytotoxic activities in leukemic cells. The antioxidant properties were evaluated using a DPPH free radical scavenging assay and by examining the extract's inhibition of AAPH-induced lipid peroxidation in human erythrocytes. Its cytotoxicity and possible mechanisms of action were assessed in Jurkat and K562 leukemic cell lines. The ethanol extract contained flavonoids, such as epigallocatechin, epicatechin, kaempferol heteroside, rutin, and dimeric and trimeric proanthocyanidin derivatives. The extract exhibited antioxidant activity by scavenging free radicals and antihemolytic action, and it decreased malondialdehyde content in human erythrocytes. Furthermore, the extract also induced leukemic cell death by activating intracellular calcium and caspase-3, decreasing mitochondrial membrane potential, and arresting the cell cycle in S and G2 phases. Hence, S. velutina leaf extract contains antioxidant and antileukemic biomolecules with potential applications in diseases associated with oxidative stress and in the inhibition of tumor cell proliferation.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27803764 PMCID: PMC5075628 DOI: 10.1155/2016/8405957
Source DB: PubMed Journal: Oxid Med Cell Longev ISSN: 1942-0994 Impact factor: 6.543
Figure 1UFLC-DAD-ESI-QTOF-micrOTOF QII chemical profiling (negative mode) of an ethanol extract of S. velutina leaves. (a) Base peak chromatograms (BPC). (b) Extract ion chromatogram (EIC) of m/z 305. (c) EIC of m/z 289. (d) EIC of m/z 593. (e) EIC of m/z 609. (f) EIC of m/z 545. (g) EIC of m/z 529. (h) EIC of m/z 513. (i) EIC of m/z 785. (j) EIC of m/z 769.
Compounds identified in ESV by UFLC-DAD-ESI-QTOF-micrOTOF QII.
| ID | Time (min) | UV | [M-H]−
| Molecular formula | Error (ppm) | MS/MS | Compound |
|---|---|---|---|---|---|---|---|
| 1 | 1.1 | — | 341.1086 | C12H20O11 | 0.6 | 341: 179 | Sugar derivative |
| 2 | 8.6 | 270 | 305.0660 | C15H14O7 | 2.3 | 305: 261, 219, 179, 167, 165 | Epigallocatechin |
| 3 | 12.5 | 280 | 289.0714 | C15H14O6 | 1.3 | 289: 245, 205, 203 | Epicatechin |
| 4 | 19.1 | 270/346 | 593.1524 | C27H30O15 | 2.1 | 593: 447, 285 | Kaempferol- |
| 5 | 19.7 | 270/346 | 609.1450 | C27H30O16 | 1.9 | 609: 463, 301 | Rutin |
| 6 | 20.5 | 280 | 545.1440 | C30H26O10 | 2.5 | 545: 305, 239, 219, 167, 165 | Cassiaflavan-epigallocatechin |
| 7 | 20.8 | 280 | 545.1440 | C30H26O10 | 2.5 | 545: 305, 239, 219, 167, 165 | Cassiaflavan-epigallocatechin |
| 8 | 21.2 | 268/338 | 593.1522 | C27H30O15 | 1.6 | 593: 447, 285 | Kaempferol- |
| 9 | 22.3 | 270/342 | 593.1521 | C27H30O15 | 1.5 | 593: 447, 285 | Kaempferol- |
| 10 | 22.6 | 280 | 529.1489 | C30H26O9 | 2.9 | 529: 289, 245, 239, 203 | Cassiaflavan-epicatechin |
| 11 | 23.5 | 280 | 529.1484 | C30H26O9 | 3.7 | 529: 289, 245, 239, 203 | Cassiaflavan-epicatechin |
| 12 | 24.9 | 280 | 529.1489 | C30H26O9 | 2.9 | 529: 267, 257, 239, 151 | Naringenin-afzelechin |
| 13 | 28.3 | 280 | 513.1551 | C30H26O8 | 0.8 | 513: 267, 255, 239 | Cassiaflavan-afzelechin |
| 14 | 28.8 | 280 | 513.1541 | C30H26O8 | 2.8 | 513: 267, 255, 239 | Cassiaflavan-afzelechin |
| 15 | 30.2 | 280 | 785.2266 | C45H38O13 | 3.4 | 785: 435, 305, 239 | Cassiaflavan-cassiaflavan-epigallocatechin |
| 16 | 30.4 | 280 | 785.2285 | C45H38O13 | 1.7 | 785: 435, 305, 239 | Cassiaflavan-cassiaflavan-epigallocatechin |
| 17 | 30.5 | 280 | 785.2255 | C45H38O13 | 2.0 | 785: 435, 305, 239 | Cassiaflavan-cassiaflavan-epigallocatechin |
| 18 | 31.1 | 280 | 769.2310 | C45H38O12 | 2.6 | 769: 529, 419, 289 | Cassiaflavan-cassiaflavan-epicatechin |
| 19 | 31.3 | 280 | 769.2303 | C45H38O12 | 1.6 | 769: 529, 419, 289 | Cassiaflavan-cassiaflavan-epicatechin |
| 20 | 31.5 | 280 | 769.2295 | C45H38O12 | 0.6 | 769: 377, 267, 239 | Cassiaflavan-naringenin-afzelechin |
| 21 | 31.7 | 280 | 769.2310 | C45H38O12 | 2.6 | 769: 377, 267, 239 | Cassiaflavan-naringenin-afzelechin |
| 22 | 31.8 | 280 | 769.2297 | C45H38O12 | 0.9 | 769: 377, 267, 239 | Cassiaflavan-naringenin-afzelechin |
IC50 and maximal DPPH radical scavenging activity of standard antioxidants and of ESV.
| Sample | IC50 ( | Maximal inhibition | |
|---|---|---|---|
| % |
| ||
| Ascorbic acid | 2.6 ± 0.8 | 90.9 ± 1.6 | 10 |
| BHT | 21.3 ± 1.2 | 92.4 ± 1.2 | 250 |
| ESV | 6.3 ± 1.3 | 92.4 ± 0.4 | 25 |
Values are means ± SEM.
Figure 2Hemolysis and MDA content in human erythrocytes incubated for 5 hours with ascorbic acid (AA) and ESV (50–125 μg/mL). (a) Hemolytic activity of ESV in the absence of AAPH. (b) Antihemolytic activity after addition of AAPH. (c) Malondialdehyde (MDA) concentration (nM/mL) after addition of the oxidizing agent. P < 0.05 compared to the AAPH-only control (erythrocytes incubated with oxidant only).
Figure 3Viability of leukemic Jurkat (a) and K562 (b) cells after treatment with different concentrations of ESV. P < 0.05 compared to the untreated control group.
Figure 4Cell death profiles of ESV-treated Jurkat (a) and K562 (b) cells. Anx−/PI−, viable cells; Anx+/PI−, apoptotic cells; Anx−/PI+, necrotic cells; and Anx+/PI+, late apoptotic cells. P < 0.05 compared to the respective control groups.
Figure 5Mitochondrial membrane potential of leukemic Jurkat (a) and K562 (b) cells treated with different ESV concentrations. P < 0.0001 compared to the untreated control group.
Figure 6Histogram (a) and representative graph (b) of caspase-3 activation in ESV-treated Jurkat cells. P < 0.0001 compared to the untreated control group.
Figure 7Involvement of caspases (via the pan-caspase inhibitor Z-VAD-FMK) and intracellular calcium (using the chelator BAPTA-AM) in ESV-induced Jurkat cell cytotoxicity. P < 0.05 compared to the untreated control group. # P < 0.05 compared to the ESV group.
Figure 8Histogram (a) and representative graph (b) of cell cycle distribution after 24 h of treatment with ESV. P < 0.05 and P < 0.001 compared to the untreated control group.